February 18, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq ... collaborated with researchers from Wellcome Sanger Institute to release data from the largest and most diverse study to ...

O n Wednesday, BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ...

NEW YORK, NY / / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

GeneDx Holdings Corp. (NASDAQ:WGS) is a growth business. Having delivered a strong end to 2024, its outlook for 2025 points to another year of robust growth ahead. However, the business isn't ...

GENEDX ($WGS) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of $0.70 per share, beating estimates of $0.16 by $0.54. The ...

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.59 per share a year ago.

GeneDx has a big market in mind for its genetic ... we’ve diagnosed your child with a form of epilepsy and we’re able to intervene now before your child has a seizure. The Associated Press ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the ...